Mrkt BUZZ DanCann Pharma: Pilot programme extended = good news
26 maj 2021
Read the commentary here:
Yesterday the Danish Ministry of Health announced the extension of the pilot programme for medical cannabis. All political parties have promised to support it:
“It has been agreed that the trial scheme with medical cannabis will be extended for four years with regard to doctors’ possibility to prescribe medical cannabis to patients. It has been agreed that the pilot scheme will be made permanent with regard to the possibility for companies to grow cannabis for medical use.”
DanCann was founded right after the Danish medical cannabis pilot programme was initiated in January 2018. In our initial coverage, we wrote:
The published evaluation suggests four possible scenarios when the pilot programme ends in December 2021:
- The programme will continue as evidence of positive effects is still needed.
- The programme will be made permanent.
- Part of the programme will continue and be made permanent in parts. The programme will continue regarding prescriptions to patients and the programme will be made permanent regarding cultivation and export of medicinal cannabis.
- The programme will be terminated.
Now it is clear that the third option was chosen. The best possible outcome would have been to make the programme permanent, but this outcome is almost as good. It removes any doubts concerning the possibility to grow and handle medical cannabis in Denmark for an international market. In theory, it might be permitted to cultivate medical cannabis in Denmark but not to sell it in country. However, this seems implausible. We believe this means that it is just a matter of time before medical cannabis becomes permanently permitted in Denmark, though the exact conditions remain to be seen. Even though no-one expected the programme to be terminated, the result that was announced yesterday implies a certain de-risking of the business model.
The Danish Ministry of Health also announced that it will discuss reimbursements for patients during the next year. This is an important factor as higher reimbursement will make medical cannabis more affordable. Today, only 50 percent of the costs up DKK 20 000 are reimbursed. One remaining issue is that only one medical cannabis product per year can be approved under the programme. If medical cannabis is to take off in Denmark, this number has to be increased.
Carlsquare recently initiated coverage of Dancann Pharma with a fair value per share of DKK 6.5.
Carlsquare AB, www.carlsquare.se, hereinafter referred to as Carlsquare, conducts business with regard to Corporate Finance and Equity Research in which areas it, among other things, publishes information about companies including analyzes. The information has been compiled from sources that Carlsquare considers to be reliable. However, Carlsquare cannot guarantee the accuracy of the information. Nothing written in the analysis should be regarded as a recommendation or invitation to invest in any financial instrument, option or the like. Opinions and conclusions expressed in the analysis are intended only for the recipient.
The content may not be copied, reproduced or distributed to another person without the written approval of Carlsquare. Carlsquare shall not be held responsible for any direct or indirect damage caused by decisions made on the basis of information contained in this analysis. Investments in financial instruments provide opportunities for value increases and profits. All such investments are also subject to risks. Risks vary between different types of financial instruments and combinations of these. Historical returns should not be considered as an indication of future returns.
The analysis is not directed to U.S. persons (as defined in Regulation S of the United States Securities Act and interpreted in the United States Investment Company Act 1940) nor may it be disseminated to such persons. The analysis is also not directed to such natural and legal persons where the distribution of the analysis to such persons would result in or entail a risk of a violation of Swedish or foreign law or constitution.
The analysis is a so-called Commissioned Research Report where the analysed Company has signed an agreement with Carlsquare for analysis coverage. The analyses are published on an ongoing basis during the contract period and for a usual fixed remuneration.
Carlsquare may or may not have a financial interest in the subject of this analysis. Carlsquare values the assurance of objectivity and independence and has established procedures for managing conflicts of interest for this purpose.
The analysts Jonatan Andersson, Markus Augustsson and Richard Ramanius do not own and are not allowed to own shares in the company analysed.